Skip to main content

Animations

MJFF Publications

5931 - 5940 of 8808 Results
Title
Year
  • Year
  • 2020
  • 2023
  • 2023
  • 2016
  • 2019
  • 2021
  • 2023
  • 2015
  • 2022
  • 2023
  • Summary Details
    OPEN
    Title: Towards defining reference materials for measuring extracellular vesicle refractive index, epitope abundance, size and concentration
    Journal Name: Journal of Extracellular Vesicles
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1080/20013078.2020.1816641
    Citation Count: 122
  • Summary Details
    OPEN
    Title: A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
    Journal Name: Drugs
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s40265-023-01838-z
    Citation Count: 32
  • Summary Details
    OPEN
    Title: Association of sulfonylureas with the risk of dementia: A population‐based cohort study
    Journal Name: Journal of the American Geriatrics Society
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1111/jgs.18397
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/acn3.338
    Citation Count: 479
  • Summary Details
    OPEN
    Title: Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.27646
    Citation Count: 193
  • Summary Details
    RESTRICTED
    Title: Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson’s Disease
    Journal Name: Molecular Neurobiology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s12035-021-02371-4
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Care access and utilization among medicare beneficiaries living with Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-023-00523-y
    Citation Count: 23
  • Summary Details
    RESTRICTED
    Title: Impact of Parkinson's disease risk loci on age at onset
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26237
    Citation Count: 53
  • Summary Details
    RESTRICTED
    Title: Deep learning architectures for Parkinson's disease detection by using multi-modal features
    Journal Name: Computers in Biology and Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.compbiomed.2022.105610
    Citation Count: 36
  • Summary Details
    OPEN
    Title: High-content phenotypic screen to identify small molecule enhancers of Parkin-dependent ubiquitination and mitophagy
    Journal Name: SLAS Discovery
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.slasd.2022.12.004
    Citation Count: 11
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.